ProBioGen expands protein and virus manufacturing to drive continued growth
Advertisement
ProBioGen announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.
In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development through to commercial manufacturing. Utilizing its CHO.RiGHT® platform in combination with market-approved technologies such as the DirectedLuck® transposase and the ADCC enhancement GlymaxX®, ProBioGen reinforces its position as a reliable partner in the industry. With this investment the company strengthens its footprint in the market and is advancing its state-of-the-art facilities across two manufacturing sites.
In the viral vector arena, ProBioGen is building on a broad experience in developing proprietary viral manufacturing platforms to offer solutions that go beyond standard processes. The company provides tailored cell lines for producing viral vectors and virus-like particles (VLPs). This includes customized stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) production, addressing the unique challenges of emerging therapeutic platforms and enabling the creation of next-generation therapies with precision and efficiency.
"These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer's needs.", explained Dr. Alfred Merz, Chief Executive Officer at ProBioGen.
Most read news
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Sensirion opens additional production building in Debrecen

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus

CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation

New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase

Managing Director Peter Sölkner leaves Vetter - Managing Director Carsten Press takes over the relevant departments

Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand - Albert M. Baehny will retire from Lonza Group following a transition period

Dr. Roland Durner becomes new CEO of Bioengineering AG

GDCh Award for Biocatalysis for Sebastian Gergel

Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025
